Preventive and therapeutic HPV vaccines

Current Opinion in Investigational Drugs

Volumn 8, Issue 12, 2007, Pages 1038-1050

  Monie, A ^a   Hung, C F ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cervical cancer; HPV; Vaccine

Indexed keywords

3 O DEACYL 4' MONOPHOSPHORYL LIPID A; ADJUVANT; ALUMINUM SALT; DENDRITIC CELL VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN 65 HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E7 VACCINE; HEAT SHOCK PROTEIN 70; HUMAN PAPILLOMAVIRUS TYPE 16 CAPSID PROTEIN L1 VIRUS LIKE PARTICLE RECOMBINANT; HUMAN PAPILLOMAVIRUS TYPE 16 CAPSID PROTEIN L2 PROTEIN E6 E7 VACCINE; HUMAN PAPILLOMAVIRUS TYPE 16 CAPSID PROTEIN L2 VIRUS LIKE PARTICLE RECOMBINANT; HUMAN PAPILLOMAVIRUS TYPE 6 CAPSID PROTEIN L2 PROTEIN E7 VACCINE; LIPOPEPTIDE; LIPOPROTEIN D HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E7 VACCINE; LIPOSOME; LIVE VACCINE; NEUTRALIZING ANTIBODY; RNA VACCINE; SGN 00101; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; WART VIRUS CAPSID PROTEIN L1 VIRUS LIKE PARTICLE RECOMBINANT VACCINE; WART VIRUS VACCINE; ZYC 101A;

ADJUVANT THERAPY; CAUSE OF DEATH; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DRUG SAFETY; EPITHELIUM CELL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; NONHUMAN; REVIEW; THERAPY EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MODELS, IMMUNOLOGICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 36849084617     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin (1999) 49(1)33-64.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 189(1):12-19. • This paper reports that, worldwide, more than 99% of cervical carcinomas are associated with HPV, suggesting that HPV may be a cause of cervical cancer.
3. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology (2004) 324(1):17-27.
4. Roden R, Wu TC: How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 6(10):753-763.
5. zur Hausen H: Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer (2002) 2(5):342-350.
6. Hagensee M, Galloway D: Growing human papillomaviruses and virus-like particles in the laboratory. Papillomavirus Rep (1993) 4:121-124.
7. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA (1992) 89(24):12180-12184.
8. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, Schiller JT: Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 67(12):6929- 6936.
9. Christensen ND, Kreider JW: Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol (1990) 64(7):3151-3156.
10. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA (1995) 92(25):11553-11557.
11. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR: Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 69(6):3959-3963.
12. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology (1996) 219(1):37-44.
13. Shope RE: Immunization of rabbits to infectious papillomatosis. J Exp Med (1937) 65(22):219-231.
14. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 347(21):1645-1651 • This paper describes a controlled trial of HPV L16 VLPs, which produced 100% effective protection from persistent HPV infection. This trial is the first to demonstrate protection against natural transmission of oncogenic HPV after vaccination with L1 VLPs.
15. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. US FDA, Rockville MD, USA (2006). http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html • This press release reports the US FDA licensing of the first HPV L1 VLP recombinant vaccine (Gardasil) developed by Merck.
16. Product approval information - licensing action. US FDA, Rockville, MD, USA (2007) http://www.fda.gov/cber/products/hpvmer060806qa. htm • This press release reports the US FDA approval of Gardasil, the first quadrivalent HPV L1 VLP recombinant vaccine developed by Merck.
17. GlaxoSmithKline plc: 2Q results 2007: Presentation to analysts and investors. Company Presentation (2007): July 25.
18. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE et al: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 6(5):271-278.
19. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS et al: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet (2007) 369(9580):2161-2170.
20. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet (2006) 367(9518):1247-1255.
21. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A et al: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer (2006) 95(11):1459-1466.
22. Gall, SA, Teixeira, J, Wheeler, CM, Naud P, Harper DM, Franco EL, Quint W, Zahaf T, Schuind A, Jenkins D, Dubin D: Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. Am Assoc Cancer Res (2007) 98: Abs 4900.
23. FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 356(19):1915-1927. •• This paper reports results from a phase III clinical trial conducted to evaluate a prophylactic quadrivalent vaccine against HPV types 6, 11, 16 and 18. This vaccine significantly reduced the occurrence of high-grade CIN related to HPV-16 or HPV-18 in young women not previously infected with HPV.
24. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 356(19):1928-1943. •• This paper reports results from a phase III clinical trial conducted to evaluate the efficacy of a prophylactic quadrivalent vaccine in preventing anogenital disease associated with HPV types 6,11, 16 and 18. This vaccine significantly reduced the incidence of HPV-associated anogenital disease in young women.
25. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT et al: Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine (2006) 24(33-34):5937-5949.
26. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT: In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 70(9):5875-5883.
27. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC: Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell (2000) 5(3):557-567.
28. Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL: Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol (1998) 72(7):6151-6154.
29. Li M, Cripe TP, Estes PA, Lyon MK, Rose RC, Garcea RL: Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: Characterization of protein domains involved in DNA binding and capsid assembly. J Virol (1997) 71(4):2988-2995.
30. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP: Cutting edge: Priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol (2005) 174(5):2476-2480.
31. Nardelli-Haefliger D, Lurati F, Wirthner D, Spertini F, Schiller JT, Lowy DR, Ponci F, De Grandi P: Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine (2005) 23(28):3634-3641.
32. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T: Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol (1999) 73(7):6188-6190.
33. Kawana K, Kawana Y, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T: Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine (2001) 19(11-12):1496-1502.
34. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB: Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virol (2005) 337(2):365-372.
35. Roden RB, Yutzy WHt, Fallon R, Inglis S, Lowy DR, Schiller JT: Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virol (2000) 270(2):254-257. • This paper presents evidence of cross-reactive neutralizing epitopes in L2, providing a rationale for developing L2-specific vaccines for the control of a wide spectrum of HPV infections.
36. Embers ME, Budgeon LR, Culp TD, Reed CA, Pickel MD, Christensen ND: Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins. Vaccine (2004) 22(5-6):670-680.
37. Kawana K, Yasugi T, Kanda T, Kino N, Oda K, Okada S, Kawana Y, Nei T, Takada T, Toyoshima S, Tsuchiya A et al: Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine (2003) 21(27-30):4256- 4260. • This paper reports results from a clinical trial of an HPV-16 L2 vaccine, which produced cross-neutralizing antibodies to at least two HPV types, demonstrating the potential for developing L2 vaccines against multiple HPV types.
38. Crook T, Morgenstern JP, Crawford L, Banks L: Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J (1989) 8(2):513-519.
39. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA (1998) 95(4):1800-1805.
40. Peng S, Frazer IH, Fernando GJ, Zhou J: Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virol (1998) 240(1):147-157.
41. Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I: Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection. Int J Cancer (1999) 81(6):881-888.
42. Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res (2003) 63(13):3478- 3482.
43. Gerard CM, Baudson N, Kraemer K, Ledent C, Pardoll D, Bruck C: Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice. Clin Cancer Res (2001) 7(3 Suppl):838s-847s.
44. Tomson TT, Roden RB, Wu TC: Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs (2004) 5(12):1247-1261.
45. Lu Y, Zhang Z, Liu Q, Liu B, Song X, Wang M, Zhao X, Zhao Q: Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model. Biol Pharm Bull (2007) 30(1):150-156.
46. Qian X, Lu Y, Liu Q, Chen K, Zhao Q, Song J: Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6δ/mE7/TBhsp70δ fusion protein vaccine in an animal model. Immunol Lett (2006) 102(2):191-201.
47. Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG, Kast WM: Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine (2006) 24(24):5235-5244.
48. Manuri PR, Nehete B, Nehete PN, Reisenauer R, Wardell S, Courtney AN, Gambhira R, Lomada D, Chopra AK, Sastry KJ: Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine (2007) 25(17):3302-3310.
49. Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI: Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: Causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res (2007) 13(1):341-349.
50. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E et al: Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother (2000) 23(2):255-266.
51. van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam PA et al: Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 35(6):946-952.
52. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J: A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res (2000) 6(9):3406-3416.
53. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, Sette A, Trimble EL, Park RC, Marincola FM: Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res (1998) 4(9):2103-2109.
54. Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, Ng P, O'Connor VM, White O, Wendt N, Martin J, Crowley JM et al: Phase I study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine (2004) 23(2):172-181.
55. Hallez S, Simon P, Maudoux F, Doyen J, Noel JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P et al: Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother (2004) 53(7):642-650.
56. Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY: A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS (2006) 20(8):1151-1155.
57. Stressgen Biotechnologies Corp: Stressgen provides corporate and HspE7 program updates. Press Release (2006): April 19.
58. Gunn GR, Zubair A, Peters C, Pan Z-K, Wu T-C, Paterson Y: Two Listeria monocytogenes vaccine vectors that express different molecular forms of HPV-16 E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol (2001) 167(11):6471-6479.
59. Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL: Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer (2002) 102(6):629-637.
60. Jabbar IA, Fernando GJ, Saunders N, Aldovini A, Young R, Malcolm K, Frazer IH: Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine (2000) 18(22):2444-2453.
61. Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, Nardelli-Haefliger D: Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology (2001) 279(1):354-360.
62. Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM: Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother (2007) 56(7):997-1007.
63. Baez-Astua A, Herraez-Hernandez E, Garbi N, Pasolli HA, Juarez V, Zur Hausen H, Cid-Arregui A: Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses. J Virol (2005) 79(20):12807-12817.
64. Ling M, Wu TC: Therapeutic human papillomavirus vaccines. In Cervical Cancer: From Etiology to Prevention. Rohan TE, Shah KV (Eds), Kluwer Academic Publishers, Dordrecht, the Netherlands (2004) 1:345-376.
65. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E et al: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 347(9014):1523-1527.
66. Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, Evans AS, Mason M: Clinical studies of human papilloma vaccines in cervical cancer. Adv Exp Med Biol (2001) 495:419-427.
67. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K et al: Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 8(12):3676-3685.
68. Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL: Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 63(18):6032-6041.
69. Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA et al: Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res (2003) 9(14):5205-5213.
70. Davidson EJ, Faulkner RL, Sehr P, Pawlita M, Smyth LJ, Burt DJ, Tomlinson AE, Hickling J, Kitchener HC, Stern PL: Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine (2004) 22(21-22):2722-2729.
71. Xenova Group plc: Drug development update: Xenova Group. Company Communication (2003): October 13.
72. Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R: Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther (2004) 15(5):421-431.
73. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzman CC, Jimenez R, Reyes L, Morosoli G, Verde ML, Rosales R: Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther (2006) 13(6):592-597.
74. Albarran YCA, de la Garza A, Cruz Quiroz BJ, Vazquez Zea E, Diaz Estrada I, Mendez Fuentez E, Lopez Contreras M, Andrade-Manzano A, Padilla S, Varela AR, Rosales R: MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: A phase I/II study. BioDrugs (2007) 21(1):47-59.
75. Doan T, Herd KA, Lambert PF, Fernando GJ, Street MD, Tindle RW: Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization. Cancer Res (2000) 60(11):2810-2815.
76. Murakami M, Gurski KJ, Marincola FM, Ackland J, Steller MA: Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res (1999) 59(6):1184-1187.
77. Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP: Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med (2002) 346(22):1752-1753.
78. Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ: HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol (2006) 100(3):469-478.
79. Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Durst M, Schneider A, Kaufmann AM: Dendritic cell-based tumor vaccine for cervical cancer II: Results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol (2003) 129(9):521-530.
80. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA: DNA vaccines. Annu Rev Immunol (1997) 15:617-648.
81. Gurunathan S, Klinman DM, Seder RA: DNA vaccines: Immunology, application, and optimization. Annu Rev Immunol (2000) 18:927-974.
82. Hung CF, Wu TC: Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther (2003) 5(1):20-24.
83. Tsen SW, Paik AH, Hung CF, Wu TC: Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 6(2):227-239.
84. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N et al: Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A phase I study of ZYC101. Clin Cancer Res (2002) 8(5):1028-1037. • This paper reports the first therapeutic HPV DNA vaccine clinical trial in patients with anal dysplasia.
85. Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, Muderspach LI, Cole GA, Crowley-Nowick PA: Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol (2003) 188(4):916-926.
86. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML, Beach KJ: ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol (2004) 103(2):317-326.
87. Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljestrom P: Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol (1998) 16(6):562-565.
88. Cheng W-F, Hung C-F, Chai C-Y, Hsu K-F, He L, Ling M, Wu T-C: Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol (2001) 75(5):2368-2376.
89. Cheng W-F, Hung C-F, Hsu K-F, Chai C-Y, He L, Ling M, Slater LA, Roden RBS, Wu T-C: Enhancement of Sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Human Gene Ther (2001) 12(3):235-252.
90. Cheng W-F, Hung C-F, Hsu K-F, Chai C-Y, He L, Rice CM, Ling M, Wu T-C. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol (2001) 166(10):6218-6226.
91. Hsu KF, Hung CF, Cheng WF, He L, Slater LA, Ling M, Wu TC: Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther (2001) 8(5):376-383.
92. Kim TW, Hung CF, Juang J, He L, Hardwick JM, Wu TC: Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Ther (2004) 11(3):336-342.
93. Herd KA, Harvey T, Khromykh AA, Tindle RW: Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour. Virology (2004) 319(2):237-248.
94. Varnavski AN, Young PR, Khromykh AA: Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors. J Virol (2000) 74(9):4394-4403.
95. Kuck D, Leder C, Kern A, Muller M, Piuko K, Gissmann L, Kleinschmidt JA: Efficiency of HPV 16 L1/E7 DNA immunization: Influence of cellular localization and capsid assembly. Vaccine (2006) 24(15):2952- 2965.
96. Lacey CJ, Thompson HS, Monteiro EF, O'Neill T, Davies ML, Holding FP, Fallon RE, Roberts JS: Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis (1999) 179(3):612-618.
97. Thompson HS, Davies ML, Holding FP, Fallon RE, Mann AE, O'Neill T, Roberts JS: Phase I safety and antigenicity of TA-GW: A recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine (1999) 17(1):40-49.
98. Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ: Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: Infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis (2005) 192(12):2099-2107.
99. de Jong A, O'Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR, Dobson JA, Jack LC, St Clair Roberts JA, Offringa R, van der Burg SH, Hickling JK: Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine (2002) 20(29-30):3456- 3464.
100. Cantab Pharmaceuticals plc: Drug development pipeline: TH-GW/TA-GW. Company Communication (2000): October 24.
101. Gambhira R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RB: Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 66(23):11120-11124.
102. Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A et al: Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 10(9):2954-2961.
103. Fiander AN, Tristram AJ, Davidson EJ, Tomlinson AE, Man S, Baldwin PJ, Sterling JC, Kitchener HC: Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: Clinical results from a multicenter phase II trial. Int J Gynecol Cancer (2006) 16(3):1075-1081.
104. Zhang LF, Zhou J, Chen S, Cai LL, Bao QY, Zheng FY, Lu JQ, Padmanabha J, Hengst K, Malcolm K, Frazer IH: HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine (2000) 18(11-12):1051-1058.
105. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC: A phase 1 study of a recombinant virus like particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis (2001) 183(10):1485- 1493.
106. Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM, Barr E, Smith PR, Chiacchierini L, DiCello A, Jansen KU: Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: Correlation with competitive radioimmunoassay titer. J Infect Dis (2001) 184(9):1183-1186.
107. Emeny RT, Wheeler CM, Jansen KU, Hunt WC, Fu TM, Smith JF, MacMullen S, Esser MT, Paliard X: Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol (2002) 76(15):7832-7842.
108. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J et al: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 93(4):284-292.
109. Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA et al: Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis (2003) 188(2):327-338.
110. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P: Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst (2003) 95(15):1128-1137.
111. Nardelli-Haefliger D, Roden R, Balmelli C, Potts A, Schiller J, De Grandi P: Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol (1999) 73(11):9609-9613.
112. Poland GA, Jacobson RM, Koutsky LA, Tamms GM, Railkar R, Smith JF, Bryan JT, Cavanaugh PF Jr, Jansen KU, Barr E: Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: A 2-year randomized controlled clinical trial. Mayo Clin Proc (2005) 80(5):601-610.
113. Brown DR, Fife KH, Wheeler CM, Koutsky LA, Lupinacci LM, Railkar R, Suhr G, Barr E, Dicello A, Li W, Smith JF et al: Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine (2004) 22(21-22):2936-2942.
114. Fife KH, Wheeler CM, Koutsky LA, Barr E, Brown DR, Schiff MA, Kiviat NB, Jansen KU, Barber H, Smith JF, Tadesse A et al: Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine (2004) 22(21-22):2943-2952.
115. Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, Jansen KU, Allende M, Taddeo FJ, Skulsky D, Barr E: A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine (2004) 22(23-24):3004-3007.
116. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM et al: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet (2004) 364(9447):1757-1765.
117. PATRICIA: Trial launched of new vaccine aimed at preventing cervical cancer. GlaxoSmithKline plc, Middlesex, UK (2006). http://www.gsk.com/ ControllerServlet?appId=4&pageId=402&newsid=251
118. Brown DR, Ault KA, Wheeler C, Jansen KU, Smith JF, Barr E, DiCello A, Nelson MR, Railkar R: A dose-ranging study of the safety and immunogenicity profiles of a quadrivalent HPV (types 6, 11, 16, and 18) L1 VLP candidate vaccine in young healthy women. International Papillomavirus Conference (2001) 19: Abs O-51.
119. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E: Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol (2006) 107(1):18-27.
120. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA: Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) Hsp65 and HPV16 E7. Clin Exp Immunol (2000) 121(2):216-225.
121. Adams M, de Jong A, Havabi H, Lippetz C, Jasani B, Man S, Fiander A, Bailey-Wood R, van der Burg SH: In vivo induction of HPV 16 specific CTL and T helper responses in patients with advanced cervical cancer using autologous dendritic cells pulsed with tumour lysate. International Papillomavirus Conference (2001) 19: Abs P-99.
122. Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA, Wu TC: Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 11(12):1011-1018.
123. Kim TW, Hung CF, Zheng M, Boyd DA, He L, Pai SI, Wu TC: A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response. J Biomed Sci (2004) 11(4):493-499.
124. Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M, Wu TC: Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol (2001) 166(9):5733-5740.
125. Kim TW, Lee JH, He L, Boyd DA, Hung CF, Wu TC: DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen. Hum Gene Ther (2005) 16(1):26-34.
126. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L, Wu TC: Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 21(25-26):4036-4042.
127. Kang TH, Lee JH, Song CK, Han HD, Shin BC, Pai SI, Hung CF, Trimble C, Lim JS, Kim TW, Wu TC: Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 67(2):802-811.
128. Hung CF, Cheng WF, He L, Ling M, Juang J, Lin CT, Wu TC: Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res (2003) 63(10):2393-2398.
129. Hung CF, Hsu KF, Cheng WF, Chai CY, He L, Ling M, Wu TC: Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res (2001) 61(3):1080-1088.
130. Brulet JM, Maudoux F, Thomas S, Thielemans K, Burny A, Leo O, Bex F, Hallez S: DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection. Eur J Immunol (2007) 37(2):376-384.
131. Wu TC: Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer. Eur J Immunol (2007) 37(2):310-314.
132. Hung CF, Tsai YC, He L, Wu TC: DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 15(6):1211-1219. • This paper describes a novel strategy to enhance DNA vaccine potency by inducing a strong CD4+ T helper cell immune response.
133. Lin CT, Tsai YC, He L, Calizo R, Chou HH, Chang TC, Soong YK, Hung CF, Lai CH: A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and antitumor activity. J Biomed Sci (2006) 13(4):481-488.
134. Liu WJ, Gao F, Zhao KN, Zhao W, Fernando GJ, Thomas R, Frazer IH: Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology (2002) 301(1):43-52.
135. Huang CH, Peng S, He L, Tsai YC, Boyd DA, Hansen TH, Wu TC, Hung CF: Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 12(15):1180-1186. • This paper describes an innovative strategy of bypassing antigen processing as a method for generating stable antigen presentation in DCs, thus enhancing DNA vaccine potency.
136. Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM, Kumar S, Wu TC: Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 112(1):109-117.
137. Kim TW, Lee JH, He L, Boyd DA, Hardwick JM, Hung CF, Wu TC: Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 65(1):309-316. • This study represents an innovative strategy to enhance DNA vaccine potency by prolonging DC survival to enhance T-cell interaction.
138. Hung C-F, Hsu K-F, Cheng W-F, Chai C-Y, He L, Ling M, Wu T-C: Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Flt3-ligand. Cancer Research (2001) 61(3):1080-1088.
139. Kim MS, Sin JI: Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology (2005) 116(2):255-266.